Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna to Test Variant-Specific Vaccine Candidate

11/26/2021 | 03:55pm EST

By Josh Beckerman

Moderna Inc. discussed plans to address the Omicron Covid-19 variant, including a new variant-specific vaccine candidate known as mRNA-1273.529.

The company said it is testing three vaccine booster candidates against the variant.

The Omicron variant "includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape," the company said. "The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity," Moderna said.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

11-26-21 1555ET

All news about MODERNA, INC.
12:54pChina's Xi rejects 'Cold War mentality,' pushes cooperation
AQ
11:38aIsraeli study shows 4th shot of COVID-19 vaccine less effective on Omicron
RE
10:45aPreliminary study at israeli hospital shows fourth shot of pfizer/biontech or moderna v..
RE
10:14aModerna To Start Clinical Development Of Vaccine Targeting Omicron Variant
MT
08:59aModerna CEO says data for Omicron-specific shot likely available in March
RE
07:20aModerna ceo says expects to share clinical data on omicron specific vaccine in developm..
RE
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/16OMICRON-SPECIFIC VACCINE LIKELY TO C : Sharma
AQ
01/14INSIDER SELL : Moderna
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 480 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 706 M - -
P/E ratio 2021 7,75x
Yield 2021 -
Capitalization 83 008 M 83 008 M -
EV / Sales 2021 4,19x
EV / Sales 2022 2,97x
Nbr of Employees 1 300
Free-Float -
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 204,73 $
Average target price 273,06 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684
CELLTRION, INC.-19.19%20 026